Abstract: An associative memory circuit including a first memristor, a second memristor, a fixed value resistor R, and an operational comparator. One terminal of the first memristor is a first input terminal of the associative memory circuit, and the other terminal of the first memristor is connected to a first input terminal of the operational comparator. One terminal of the second memristor is a second input terminal of the associative memory circuit, and the other terminal of the second memristor is connected to the first input terminal of the operational comparator. One terminal of the fixed value resistor is connected to the first input terminal of the operational comparator, and the other terminal of the fixed value resistor is connected to the ground. A second input terminal of the operational comparator is connected to a reference voltage.

Abstract: An ultra-low power transmitter applied in multi-channel frequency shift keying (FSK) communication is provided. The transmitter includes a fixed-frequency generation device, a low-frequency frequency synthesizer, and an injection locking device. The fixed-frequency generation device provides a reference frequency to the low-frequency frequency synthesizer. The frequency synthesizer divides the reference frequency with corresponding divisors for generating a plurality of divided frequency signals. Then, the divided frequency signals are injected into the injection locking device. The injection locking device will lock at the average frequency of previously mentioned divided frequencies. Wherein, the injection locking device filters the high frequency noise, which is produced by the frequency synthesizer, at the time of the injection locking. The ultra-low power transmitter obtains a high-frequency transmitted signal by using the frequency-locked signal.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.

Abstract: One implementation described herein includes a system for providing at least an estimate of substance concentrations in a bodily fluid. The system comprises a first emitter for generating signals using a first sensing modality, a first detector configured to detect signals from said first emitter that have travelled through the bodily fluid and output a corresponding first detector signal; a second emitter for generating signals using a second sensing modality different to said first sensing modality, a second detector configured to detect signals from said second emitter that have travelled through the bodily fluid and output a corresponding second detector signal; and a processor configured to receive the detector signals from said first and second detectors, to process said signals and to output an indication of at least an estimate of the concentration of said substance in said bodily fluid.

Abstract: Aspects of solar energy forecasting are described herein. In one embodiment, a method of solar energy forecasting includes masking at least one sky image to provide at least one masked sky image, where the at least one sky image includes an image of at least one cloud captured by a sky imaging device. The method further includes geometrically transforming the at least one masked sky image to at least one flat sky image based on a cloud base height of the at least one cloud. Once the cloud is identified, the motion of the at least one cloud may be determined over time. Rays of solar irradiance can be traced using the identified clouds and cloud motion and a solar energy forecast generated by ray tracing the irradiance of the sun upon a geographic location according to the motion of the at least one cloud.

Abstract: High-resolution 3D optical polarization tractography (OPT) images of the internal fiber structure of a target tissue. Manipulation of dual-angle imaging data of the fiber orientation inside a target tissue leads to the determination of 3D imaging properties of the target tissue, allowing transmission of the 3D image properties of the target tissue to an OPT processor to produce high-resolution 3D images.

Abstract: The present invention provides methods and compositions for diagnosing and predicting the occurrence of ischemia. For example, the present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient neurological events (TNE) as ischemic or non-ischemic.

Abstract: Systems, methods, and media for extracting information and a display image from two captured images are provided, in some embodiments, systems for extracting information and a display image from two captured images are provided, the systems comprising: a rolling shutter sensor; and a hardware processor coupled to the rolling shutter sensor that is configured to: cause the roiling shutter sensor to capture two captured images; receive the two captured images; and extract the information, and the display image from the two captured images, wherein the information is represented in the captured images as a flicker pattern.

Abstract: Methods useful in the treatment of cytotoxic insults such as excitotoxic injury, ischemic injury, and hypoxic injury are disclosed. The methods involve the treatment of the cytotoxic insult with a pharmaceutical composition comprising poly-ICLC.

Abstract: The disclosure provides for compositions, systems, and methods of cell expansion, stimulation and/or differentiation. The disclosure further provides for a mesh substrate and associated methods capable of stimulating cell expansion, for example, T cell or stem cell expansion. In another aspect, the disclosure provides for an electrospun mesh substrate and methods of using thereof comprising a silicone rubber composition, for example, polydimethylsiloxane, PLC, or combinations thereof.

Abstract: The present invention provides a method for preparing a drug composition, which includes steps of dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug into a solvent to form a mixture solution, and the pH value of the mixture solution is adjusted to a range without precipitating the hydrophilic drug(s) and the hydrophobic drug(s), wherein the amphiphilic chitosan derivative is modified by a plurality of hydrophilic group(s) and a plurality of hydrophobic group(s); and after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH value of the mixture solution is between pH 6 to 7. The hydrophilic drug(s) and the hydrophobic drug(s) are encapsulated simultaneously by one-pot synthesis, and the protein could be modified by one-pot synthesis to provide a drug composition with multiple functions.

Abstract: A substrate treatment system for treating a substrate, includes: a treatment station in which a plurality of treatment apparatuses which treat the substrate are provided; an interface station which directly or indirectly delivers the substrate between an exposure apparatus which is provided outside the substrate treatment system and performs exposure of patterns on a resist film on the substrate, and the substrate treatment system; a light irradiation apparatus which performs post-exposure using UV light on the resist film on the substrate after the exposure of patterns is performed; and a post-exposure station which houses the light irradiation apparatus and is adjustable to a reduced pressure or inert gas atmosphere, wherein the post-exposure station is connected to the exposure apparatus directly or indirectly via a space which is adjustable to a reduced pressure or inert gas atmosphere.

Abstract: A system and method for using the system that permits a severely-ability challenged user to communicate with his or her environment using a brain-controlled interface. In one embodiment, the user's functional capability with the system is assessed to enhance candidate optimization for system benefit.

Abstract: A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: There is provided a compound of formula I, having the structure: wherein R1 to R5 have the meanings given in the description.

Abstract: The present application provides a method for simultaneously synthesizing a biological flocculant with polysaccharide and ?-PGA as the active components by using Bacillus licheniformis. Bacillus licheniformis is inoculated to a slant culture medium to be cultured; a single colony on a fresh plate is inoculated to a seed culture medium to be cultured; and a seed fermentation broth is inoculated to a fermentation culture medium to be cultured, and then the biological flocculant having two different components is obtained. The flocculant synthesized in the present invention is high in activity and good in thermal stability; and especially, the flocculation effect of polysaccharide is relatively superior under acidic and neutral conditions, and the flocculation activity of ?-PGA is relatively higher under neutral and alkaline environments, which can satisfy a relatively large pH application range.

Abstract: According to example embodiments, a method includes dispersing carbon nanotubes in a mixed solution containing a solvent, the carbon nanotubes, and a dispersant, the carbon nanotubes including semiconducting carbon nanotubes, the dispersant comprising a polythiophene derivative including a thiophene ring and a hydrocarbon sidechain linked to the thiophene ring. The hydrocarbon sidechain includes an alkyl group containing a carbon number of 7 or greater. The hydrocarbon sidechain may be regioregularly arranged, and the semiconducting carbon nanotubes are selectively separated from the mixed solution. An electronic device includes semiconducting carbon nanotubes and the foregoing described polythiophene derivative.

Abstract: A DNA polymerase composition for amplifying nucleic acids can be tolerant of extreme conditions.

Abstract: A low voltage crystal oscillator (XTAL) driver with feedback controlled duty cycling for ultra low power biases an amplifier for an XTAL in the sub-threshold operating regime. A feedback control scheme can be used to bias the amplifier for an XTAL biased in the sub-threshold operating regime. The amplifier of a XTAL oscillator can be duty cycled to save power, e.g., the XTAL driver can be turned off to save power when the amplitude of the XTAL oscillation reaches a maximum value in range; but be turned back on when the amplitude of the XTAL oscillation starts to decay, to maintain the oscillation before it stops. In addition or alternatively, a feedback control scheme to duty cycle the amplifier of a XTAL oscillator can be used to monitor the amplitude of the oscillation.